Pas­sive vac­ci­na­tion? As­traZeneca spot­lights six-month pro­tec­tion with Covid-19 an­ti­body among vul­ner­a­ble group

New fol­low-up da­ta sug­gest that As­traZeneca’s long-act­ing an­ti­body can pro­tect high-risk pop­u­la­tions from con­tract­ing Covid-19 for as long as six months, beef­ing up the case …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER